Physician profile
Daniel J Heaney
NPI 1598725038
$8,439.63
in general payments reported to CMS, 2019-2025
61 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,138 · 2022: $1,514 · 2023: $1,725 · 2024: $1,307 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,787.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,128.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $729.42 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Pfizer INC. | $488.44 | 2021-2025 | |
| Glaxosmithkline, LLC. | $460.51 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Amgen INC. | $458.41 | 2021-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.30 | 2021-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $331.28 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $319.11 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $263.83 | 2021-2025 | Spravato, Xarelto |
| Bausch Health US, LLC | $261.16 | 2021-2025 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.60 | 2021-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $244.15 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.13 | 2021-2025 | |
| Lundbeck LLC | $190.84 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $190.46 | 2021-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Heaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.